Journal
CELL BIOCHEMISTRY AND BIOPHYSICS
Volume 67, Issue 1, Pages 25-43Publisher
HUMANA PRESS INC
DOI: 10.1007/s12013-013-9635-3
Keywords
Synthetic lethality; Ubiquitin; Deubiquitylating enzyme; DUB; DNA damage response; DNA repair; Drug discovery; Checkpoint control
Funding
- CRUK Program [C6/A11224]
- European Research Council
- European Community [HEALTH-F2-2010-259893]
- CRUK [C6946/A14492]
- Welcome Trust [WT092096]
- Cancer Research UK [11224] Funding Source: researchfish
Ask authors/readers for more resources
Covalent post-translational modification of proteins by ubiquitin and ubiquitin-like factors has emerged as a general mechanism to regulate myriad intra-cellular processes. The addition and removal of ubiquitin or ubiquitin-like proteins from factors has recently been demonstrated as a key mechanism to modulate DNA damage response (DDR) pathways. It is thus, timely to evaluate the potential for ubiquitin pathway enzymes as DDR drug targets for therapeutic intervention. The synthetic lethal approach provides exciting opportunities for the development of targeted therapies to treat cancer: most tumours have lost critical DDR pathways, and thus rely more heavily on the remaining pathways, while normal tissues are still equipped with all DDR pathways. Here, we review key deubiquitylating enzymes (DUBs) involved in DDR pathways, and describe how targeting DUBs may lead to selective therapies to treat cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available